Printable View
With an average cycle ( 600mgs of test and 500mgs of eq or deca ) will 10mgs of Nolva and .25mgs of L-dex effect your cycle gains?
Running 10mgs of Nolva and .25mgs of L-dex for 16wks with the cycle and bumping the nolva up to 20mgs for pct and keeping L-dex at .25
How much can it effect your results? Opinions and personal experience...
Less water will be retained. Some may argue that increased water retention can give you more leverage to push more weight, thus potential for more gains. There may be SOME truth to that, but the benefits of no water retention far outweigh what little potential, if any, there is to see more gains while bloated.
l-dex and nolv won't hinder gains at all......
Well nolva and arimidex suppress estrogen from attaching or being produced in the first place. To give you an idea estrogen is needed by the body to work with testosterone and increase muscle mass. So yes, those will affect your gains on building muscle. But like said above you will retain less water and keep yourself from any estrogen related sides. I used to prefer to take nolva only when needed but now i am thinking of taking arimidex at .25/day. I dont think you need the nolva too, just keep the nolva for PCT.
taking estrogen during a cycle is good. estrogen being higher or close to testosterone levels is bad. but when you are taking 500mg test/week your estrogen is not anywhere close. until you end your cycle and your test levels drop, but then you start PCT.
sorry correction above...not "taking estrogen"..."having estrogen"....hehe
???? like i said earlier, run both nolv and l-dex during your cycle, and during pctQuote:
Originally Posted by juicewillis
????Quote:
Originally Posted by juicewillis
another questions, 10mgs for entire cycle and 20mgs for pct. Correct...Not necessary to run 20mgs Nolva during cycle...Quote:
Originally Posted by asymmetrical1
10 mgs during cycle is fine,and 20 mgs pct.Quote:
Originally Posted by Russ616
if you will only be running Nolva then 20mg durring your cycle and PCT....... If you are using .25mg L-dex then 10mg Nolva and then 20mg durring PCT
At .25 and 20mg you should not see a major hinder in gains, however if you were to run 60mg and 1.5gm of liquidex you would probably not put on too much weight.
At 10mg of nolva and .25mg of Ldex you aren't ridding your body of estrogen....you're simply limiting it and its effects. In addition, nolva will still maintain many of the estrogenic positive effects...... even in the absence of estrogen, which isn't likely to happen anywhere near these doses.
If you are only using Nolvadex then you should run what 10 or 20.... maybe 10 then bump it to 20 if you notice any sides? And should you be increasing it for PCT to like 30-40?
if it's your only anti-e, run at 20 like mud saidQuote:
Originally Posted by 100%NATURAL-theGH
If one is prone to gyno syptoms should Arimdex definately be used along side Nolva or can you just up your dose to 20 mgs of Nolva alone to get the same effect.Just considering the price here, Nolva is much cheaper to get.
there are other benefits to running a serm and an inhibitor, such as keeping lipids in check......l-dex is just as cheap as nolvaQuote:
Originally Posted by Cyto
J Steroid Biochem Mol Biol. 2002 Apr;80(4-5):411-8. Related Articles, Links
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
Ferrari L, Martinetti A, Zilembo N, Pozzi P, Buzzoni R, La Torre I, Gattinoni L, Catena L, Vitali M, Celio L, Seregni E, Bombardieri E, Bajetta E.
Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori of Milan, Via G. Venezian, 1, 20133 Milan, Italy.
Insulin-like growth factors (IGFs) play a fundamental role in cancer development by acting in both an endocrinal and paracrinal manner, and hormone breast cancer treatments affect the IGF system by modifying circulating growth factor levels. We evaluated total IGF-1, IGF-2, IGF binding protein (IGFBP)-1 and IGFBP-3 in the blood of 34 postmenopausal advanced breast cancer patients (median age 63 years, range 41-85) treated with anastrozole, a non-steroidal structure aromatase inhibitor (NSS-AI). The plasma samples were obtained at baseline, and after 2, 4, 8 and 12 weeks of treatment. The IGFs were quantitated by means of sensitive radioimmunoassays (RIAs). IGF-1 significantly increased during anastrozole treatment (baseline versus 12 weeks, P=0.031), IGF-2 showed a trend towards an increase, and IGFBP-1 constantly but not significantly decreased; IGFBP-3 did not seem to be affected at all. The anastrozole-induced changes in IGFs and IGFBP-1 appeared to be different in the patients receiving a clinical benefit from those observed in non-responders. We have previously shown that letrozole (a different type of NSS-AI) modifies blood IGF-1 levels, and the results of this study of the biological effects of anastrozole on the components of the IGF system confirm our previous observations.